A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec
NCT07332000
This study is recruiting at 7 US sites in 6 states, according to its ClinicalTrials.gov record last updated .
Summary
Phase 2a, open-label, multi-center study evaluating biomarkers and biodistribution of aglatimagene besadenovec plus valacyclovir in men with localized, intermediate-risk prostate cancer who are planning to receive external beam radiation therapy (EBRT).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostate Cancer Patients Treated by Radiotherapy
- Prostate Cancer (Adenocarcinoma)
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Candel Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- September 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 1
- Academic Urology and Urogynecology of Arizona · Peoria, AZ
Colorado · 2
- Colorado Clinical Research · Lakewood, CO
- Urology Associates · Littleton, CO
Maryland · 1
- Chesapeake Urology Research Associates · Towson, MD
Nevada · 1
- Sheldon Freedman, MD Ltd. · Las Vegas, NV
New Jersey · 1
- Summit Health · Saddle Brook, NJ
South Carolina · 1
- START Carolinas · Myrtle Beach, SC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.